Artal Group S.A. Adc Therapeutics Sa Transaction History

Artal Group S.A.

  • $214 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$2.55 - $5.09 $2.6 Million - $5.18 Million
1,018,461 New
1,018,461 $3.22 Million
Q1 2021

May 14, 2021
SELL
$22.75 - $34.05 $2.16 Million - $3.23 Million
-95,000 Closed
0 $0
Q3 2020

Nov 13, 2020
SELL
$32.87 - $51.05 $1.35 Million - $2.09 Million
-41,000 Reduced 30.15%
95,000 $3.13 Million
Q2 2020

Aug 14, 2020
BUY
$29.65 - $46.81 $4.03 Million - $6.37 Million
136,000 New
136,000 $6.37 Million

Others Institutions Holding ADCT

# of Institutions
80
Shares Held
55.1M
Call Options Held
82.7K
Put Options Held
31.5K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $172M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email